Oxytocin vs Atosiban
Oxytocin and atosiban are pharmacologically related peptides with opposing effects on uterine contractility. Oxytocin is the endogenous uterotonic that stimulates uterine contractions; atosiban is a synthetic oxytocin analogue that competitively antagonizes the oxytocin receptor, inhibiting contractions. Understanding their competitive receptor dynamics is essential for rational tocolytic therapy selection.
Molecular Profiles
Section titled “Molecular Profiles”Oxytocin
Section titled “Oxytocin”Oxytocin is a 9-amino acid cyclic neuropeptide:
- Sequence: Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH₂ (disulfide bridge: Cys¹–Cys⁶)
- Molecular weight: ~1,007 Da
- Receptor: Oxytocin receptor (OXTR) — Gq-coupled
- Half-life: 3–5 minutes (IV)
- Effect: Uterotonic (stimulates contractions)
Atosiban
Section titled “Atosiban”Atosiban is a synthetic oxytocin analogue with three amino acid substitutions:
- Sequence: Mpa-Tyr(Ile)-Gln-Asn-Cys-Pro-Arg-Gly-NH₂
- Modifications:
- Position 1: Cys → Mercaptopropionic acid (Mpa) — removes free amino group
- Position 2: Tyr → Tyr(Ile) — bulky substituent for receptor antagonism
- Position 8: Leu → Arg — charge modification
- Molecular weight: ~994 Da
- Receptor: Oxytocin receptor (OXTR) — competitive antagonist
- Half-life: ~12 minutes (IV)
- Effect: Tocolytic (inhibits contractions)
The structural modifications convert a full OXTR agonist (oxytocin) into a competitive antagonist (atosiban) — a pharmacological transformation achieved through strategic amino acid substitutions that preserve receptor binding affinity while eliminating intrinsic activity.
Receptor Pharmacology
Section titled “Receptor Pharmacology”| Property | Oxytocin | Atosiban |
|---|---|---|
| OXTR binding affinity | High (Kd ~2 nM) | High (Ki ~3 nM) |
| Intrinsic activity | Full agonist | Antagonist (0% activity) |
| V1a receptor activity | Agonist | Partial agonist |
| V2 receptor activity | Minimal | Minimal |
| Mechanism | Activates OXTR → contractions | Blocks OXTR → inhibits contractions |
Atosiban binds OXTR with comparable affinity to oxytocin but produces no receptor activation — it acts as a pure competitive antagonist. The V1a partial agonism may contribute mild vasoconstriction, which is generally clinically insignificant.
Mechanism of Tocolysis
Section titled “Mechanism of Tocolysis”Oxytocin Receptor Signaling
Section titled “Oxytocin Receptor Signaling”Oxytocin activates OXTR on myometrial smooth muscle cells:
- Gq activation: OXTR couples to Gq → phospholipase C (PLC) activation.
- IP₃/DAG generation: PLC cleaves PIP₂ → IP₃ (calcium release) + DAG (PKC activation).
- Calcium elevation: IP₃ releases Ca²⁺ from sarcoplasmic reticulum → cytoplasmic Ca²⁺ increase.
- Contraction: Ca²⁺-calmodulin complex activates myosin light chain kinase (MLCK) → smooth muscle contraction.
Atosiban Antagonism
Section titled “Atosiban Antagonism”Atosiban blocks this cascade by competitive OXTR antagonism:
- Competitive binding: Atosiban occupies OXTR without activating it.
- Oxytocin exclusion: Endogenous oxytocin cannot access the receptor.
- Signal blockade: Gq-PLC-IP₃ cascade is not initiated.
- Contraction inhibition: Without calcium elevation, myometrial relaxation is maintained.
Clinical Evidence
Section titled “Clinical Evidence”Atosiban in Preterm Labor
Section titled “Atosiban in Preterm Labor”The pivotal atosiban trials established its role as a first-line tocolytic:
ATOSIBAN 021 International Trial:
- Atosiban (n=513) vs placebo (n=512) for preterm labor (24–33 weeks)
- Primary endpoint: Delivery within 48 hours — atosiban reduced risk by 38% (p<0.001)
- Neonatal outcomes: No significant difference in respiratory distress syndrome, intraventricular hemorrhage, or necrotizing enterocolitis
European Multicenter Trial:
- Atosiban (n=242) vs ritodrine (n=242) for preterm labor
- Tocolytic efficacy: Similar delay in delivery
- Side effects: Atosiban had significantly fewer maternal side effects (tachycardia, hyperglycemia, pulmonary edema)
Oxytocin Antagonism: Clinical Implications
Section titled “Oxytocin Antagonism: Clinical Implications”Atosiban’s tocolytic effect is time-limited — competitive antagonism can be overcome by rising endogenous oxytocin levels during labor progression. This is by design: atosiban provides temporary uterine relaxation to allow corticosteroid administration and fetal maturation, not indefinite pregnancy prolongation.
Dosing and Administration
Section titled “Dosing and Administration”| Parameter | Oxytocin (Labor Induction) | Atosiban (Tocolysis) |
|---|---|---|
| Loading dose | 1–2 mU/min IV | 6.75 mg IV bolus |
| Maintenance | 1–2 mU/min IV (titrated) | 300 µg/min IV (3 hrs) → 100 µg/min |
| Maximum dose | 20–40 mU/min | 300 µg/min |
| Duration | Until delivery | 48 hours (max) |
| Route | IV infusion | IV infusion |
Atosiban Dosing Protocol
Section titled “Atosiban Dosing Protocol”| Phase | Dose | Duration |
|---|---|---|
| Bolus | 6.75 mg (0.9 mL) IV | 1 minute |
| High-dose infusion | 300 µg/min | 3 hours |
| Low-dose infusion | 100 µg/min | Up to 45 hours |
The step-down protocol maintains competitive OXTR blockade while minimizing cumulative dose and side effects.
Side Effects
Section titled “Side Effects”| Effect | Oxytocin | Atosiban |
|---|---|---|
| Nausea | 10–15% | 3–5% |
| Vomiting | 5–10% | 1–3% |
| Tachycardia | 5–10% | 1–3% |
| Hypertension | 5–10% (high dose) | 1–5% |
| Water intoxication | Rare (high dose) | Very rare |
| Anaphylaxis | Very rare | Very rare |
| Fever | 1–3% | 1–3% |
Atosiban’s side effect profile is substantially milder than other tocolytics (ritodrine, nifedipine, magnesium sulfate), making it the best-tolerated tocolytic agent available.
Comparative Tocolytic Position
Section titled “Comparative Tocolytic Position”| Tocolytic | Mechanism | Efficacy | Tolerability | Recommendation |
|---|---|---|---|---|
| Atosiban | OXTR antagonist | Good | Excellent | First-line |
| Nifedipine | Calcium channel blocker | Good | Good | First-line alternative |
| Indomethacin | COX inhibitor | Moderate | Moderate | <32 weeks only |
| Magnesium sulfate | Calcium antagonist | Moderate | Poor | Neuroprotection |
| Ritodrine | β₂-agonist | Moderate | Poor | Rarely used |
Atosiban’s combination of efficacy and tolerability positions it as the preferred tocolytic in many guidelines, though nifedipine is an equivalent first-line alternative at lower cost.
Summary
Section titled “Summary”Oxytocin and atosiban represent the pharmacological yin and yang of uterine contractility. Oxytocin activates OXTR to stimulate contractions for labor induction; atosiban competitively blocks OXTR to inhibit contractions for tocolysis. The structural modifications that convert oxytocin from agonist to antagonist — Mpa¹, Tyr(Ile)², Arg⁸ — preserve receptor binding affinity while eliminating intrinsic activity. Atosiban’s tocolytic effect is time-limited by design, providing temporary uterine relaxation to allow corticosteroid administration and fetal maturation rather than indefinite pregnancy prolongation. Its excellent tolerability profile positions it as the first-line tocolytic for preterm labor management.